Bidirectionality of antiseizure and antipsychotic treatment: A population-based study

Eline Revdal a,b,* Gunnar Morken c,d, Inger Johanne Bakken e, Geir Bråthen a,b, Cecilie Johannesen Landmark f,g,h, Eylert Brodtkorb a,b

a Department of Neurology and Clinical Neurophysiology, St. Olav University Hospital, Trondheim, Norway
b Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway
c Department of Psychiatry, St. Olav University Hospital, Trondheim, Norway
d Department of Mental Health, Norwegian University of Science and Technology, Trondheim, Norway
e The Norwegian Directorate of Health, Norway
f Department of Pharmacy, Oslo Metropolitan University, Oslo, Norway
g The National Center for Epilepsy, Oslo University Hospital, Oslo, Norway
h Department of Pharmacology, Oslo University Hospital, Oslo, Norway

ABSTRACT

Purpose: To study the prevalence and directionality of comorbid epilepsy and psychosis in Norway.

Methods: The Norwegian Prescription Database (NorPD) provided individual-based information on all antiseizure medications (ASMs) and antipsychotic drugs (APDs) dispensed during 2004–2017. Subjects were ≥18 years of age at the end of the study period. Diagnosis-specific reimbursement codes from the 10th revision of the International Classification of Diseases/2nd edition of the International Classification of Primary Care (ICD-10/ICPC-2) combined with ATC codes were used as indicators of diagnosis. Subjects had collected ASMs for epilepsy or APDs for psychosis at least four times, at least once issued with an ICD-10 code from the specialist healthcare service. Directionality was analyzed in subjects receiving both treatments. To reduce prevalent comorbidity bias, we employed a four-year comorbidity-free period (2004–2007). The use of specific ASMs and APDs was analyzed.

Results: A total of 31,289 subjects had collected an ASM for epilepsy at least four times, 28,889 an APD for psychosis. Both the prevalence of treatment for epilepsy and of treatment for psychosis was 0.8%. Further, 891 subjects had been treated for both conditions; 2.8% with epilepsy had been treated for psychosis, and 3.1% with psychosis had been treated for epilepsy. Among 558 subjects included in the analyses of directionality, 56% had collected the first APD before an ASM, whereas 41% had collected an ASM first. During the last year prior to comorbidity onset, levetiracetam, topiramate, or zonisamide had been used for epilepsy by approximately 40%, whereas olanzapine and quetiapine were most used in patients with psychosis, and clozapine in 13%.

Conclusion: The proportion of patients with prior antipsychotic treatment at onset of epilepsy is higher than previously acknowledged, as demonstrated in this nation-wide study. Apart from a shared neurobiological susceptibility, the bidirectionality of epilepsy and psychosis may be influenced by various environmental factors, including the interaction of pharmacodynamic effects. APDs may facilitate seizures; ASMs may induce psychiatric symptoms. In patients with combined treatment, these potential drug effects should receive ample attention, along with the psychosocial consequences of the disorders. A prudent multi-professional approach is required.

© 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords: Antiseizure medications Antipsychotic drugs Epilepsy Psychosis Comorbidity Directionality

ARTICLE INFO

Article history:
Received 27 June 2022
Revised 29 August 2022
Accepted 2 September 2022
Available online 17 September 2022

Abbreviations: NorPD, The Norwegian Prescription Database; ASMs, antiseizure medications; APDs, antipsychotic drugs; ICD-10, The 10th revision of the International Classification of Diseases; ICPC-2, The 2nd edition of the International Classification of Primary Care; DDD, Defined Daily Doses; ATC code, Anatomical Therapeutic Chemical code.

* Corresponding author at: NTNU, Faculty of Medicine and Health Sciences, Department of Neuromedicine and Movement Science, N-7491 Trondheim, Norway.

E-mail addresses: Eline.revdal@ntnu.no (E. Revdal), Gunnar.morken@ntnu.no (G. Morken), Inger.johanne.bakken@helsedir.no (I.J. Bakken), Geir.brathen@ntnu.no (G. Bråthen), Cecilie.landmark@oslomet.no (C.J. Landmark), Eylert.brodtkorb@ntnu.no (E. Brodtkorb).

https://doi.org/10.1016/j.yebeh.2022.108911
1525-5050/© 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

During recent years, there has been much focus on the comorbidity of psychiatric disorders in people with epilepsy. Psychosocial and neurobiological factors are at play. Virtually all psychiatric disorders seem to occur in a higher proportion of subjects with epilepsy than in those without, and observational studies have indicated a bidirectional relationship [1]. However, estimates have varied considerably across studies depending on settings, sources of ascertainment, and diagnostic criteria. In a recent survey of patients acutely admitted to a psychiatric hospital, the lifetime prevalence of epilepsy was 3.9% [2]. An extensive meta-analysis of 58 studies of psychosis in epilepsy showed a pooled prevalence of 5.6% (range 0.02–27%). There was substantial heterogeneity across individual studies, and further population-based research was requested [3].

Historically, psychosis in epilepsy has been attributed to the consequences of having seizures and the psychosocial burden of the diagnosis [4]. Less attention was given to the onset of epilepsy in people with prior psychosis [5]. In roughly the last 10 years, growing evidence of a reciprocal relationship also for psychosis has been found in selected populations, but few studies have had the data to substantiate this bidirectionality.

Some evidence has been documented in selected samples from various countries: A Japanese study from tertiary centers of 312 patients fulfilling the diagnostic criteria for both disorders identified 23 patients diagnosed with a psychotic disorder predating the diagnosis of epilepsy, whereas the majority developed interictal psychosis in the course of confirmed epilepsy [6]. In a Swedish case–control study of 1,885 subjects from the Stockholm Epilepsy Register, the risk for developing epilepsy after hospitalization for psychosis was increased by 2.3 compared to controls [7]. A similar retrospective cohort study of hospital admissions in the UK found an elevated risk of epilepsy of 2.1 and 3.0 in two different study materials including one covering the whole of England [8]. Another study from the UK using data from a general practice research database also demonstrated an increased rate of prior psychiatric disorders, including psychosis, in people with newly diagnosed epilepsy [9]. Likewise, two US studies of elderly subjects (>65 years), suggested that premorbid psychosis was an independent risk factor for late-onset epilepsy [10,11]. A recent literature review suggests that the incidence of epilepsy in patients with schizophrenia is 4–5 times higher than that of the general population [5]. Notwithstanding, scarce scientific attention has been given to the relationship between psychosis and epilepsy onset, and the extent of this group is still not determined [3].

Hence, we set out to investigate the prevalence and directionality of comorbid epilepsy and psychosis in a population-based study of subjects receiving combined antipsychotic and antiseizure treatment of comorbid epilepsy and psychosis in a population-based study [3]. Notwithstanding, scarce scientific attention has been given to the relationship between psychosis and epilepsy onset, and the extent of this group is still not determined [3].

2. Material and methods

This was a retrospective population-based observational study using pharmacoepidemiologic data from the NorPD.

2.1. Data material

The NorPD contains individual-based information on all drugs dispensed from Norwegian pharmacies from 2004. Diagnosis-specific codes reflect reimbursable indications, such as epilepsy and psychiatric disease. The 10th revision of the International Classification of Diseases (ICD-10) and the 2nd edition of the International Classification of Primary Care (ICPC-2) were implemented from 2008.

We obtained NorPD-data with information on all ASMs defined by the Anatomical Therapeutic Chemical code (ATC code) N03A and APDs defined by ATC code N05A collected from 2004 through 2017 in subjects ≥18 years of age at the end of the study period. The dataset included pseudonymous patient identification numbers, information on sex and year of birth, ATC code (version 2018), date of dispensation, number of defined daily doses (DDDs) per prescription, and reimbursement codes.

The adult population of Norway in the years 2004–2017 was collected from Statistics Norway [12].

2.2. Identification of diagnostic groups

Subjects were categorized into two diagnostic groups based on reimbursement codes: (1) epilepsy and (2) psychosis, limited to schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders (Table 1). Four unique prescriptions of ASMs for epilepsy or APDs for psychosis were required for inclusion, of which at least one had been issued with an ICD-10 reimbursement code from the specialist healthcare service.

2.3. Directionality

In subjects with prescriptions of both ASMs and APDs (epilepsy and psychosis comorbidity), we analyzed the directionality of treatments according to the first date of dispensation of each drug. To reduce prevalent comorbidity bias, we employed a four-year comorbidity-free period for those included in the analysis of directionality, meaning that no subjects had collected treatment for both disorders during these years.

2.4. Antiseizure and antipsychotic treatment

For each subject in the comorbidity groups, we identified unique ASMs and APDs prescribed during the last twelve months before onset of treatment for each condition. We also analyzed the number of ASMs used for epilepsy and APDs for psychosis during these twelve months. Finally, we analyzed the distribution of ASMs and APDs used both by subjects with and without comorbidity during the entire study period. We calculated mean DDD/patient/day for both ASMs and APDs prescribed for epilepsy and psychosis, respectively, according to subjects with or without comorbidity. The total DDDs per year of each drug was divided by total number of users, and further divided by 365 days.

Table 1
Diagnostic group based on ATC code and reimbursement codes according to ICD-10 and ICPC-2.

| Diagnostic group | ATC code | Reimbursement codes |
|------------------|---------|---------------------|
|                  | ICD-10  | ICPC-2              |
| Epilepsy         | N03A    | G40, F20-F29, -F2   |
| Psychosis        | N05A    | N88, P72, P98, -72  |

ATC code, Anatomical Therapeutic Chemical code; ICD-10, International Classification of Diseases; ICPC-2, International Classification of Primary Care.

a ATC code N03A: Antiseizure medication.
b ATC code N05A: Antipsychotics.
c Reimbursement codes defined by The Norwegian Medicines Agency 1.9.2008: -F2/-72 "Psychosis and psychotic symptoms in psychiatric disorders".
2.5. Statistical analysis

Stata software package, Version 17.0 (StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC) was used for the data analysis. Chi Squared ($\chi^2$) test was used to test for significant association between groups of comorbidity or non-comorbidity and prescribed medication. The continuous data of the variable DDD/patient/day deviated from a normal distribution, hence the non-parametric two-sample Wilcoxon rank-sum (Mann–Whitney) test was used to compare means. A $p$-value $\leq 0.05$ was considered significant.

2.6. Ethics

The use of registry data for this study was approved by the Regional Committee for Medical and Health Research Ethics, Central Norway (2016/56 and 2018/629).

3. Results

3.1. Epilepsy

A total of 31,289 subjects had collected an ASM with a reimbursement code for epilepsy four times or more: 15,430 (49%) women and 15,859 (51%) men. The prevalence of treatment for epilepsy in the adult population of Norway was 0.8% (Table 2). By the end of the study period 4209 (13%) of the subjects had been without epilepsy treatment for more than 5 years, suggesting epilepsy in remission.

3.2. Psychosis

An APD for psychosis had been prescribed at least four times to 28,889 subjects: 13,863 (48%) women and 15,026 (52%) men. The prevalence of treatment for psychosis was also 0.8% (Table 2). By the end of the study period 4335 (15%) had not collected APDs for psychosis for at least 5 years.

3.3. Comorbid conditions

A total of 891 subjects were treated for both epilepsy and psychosis, 0.02% of the adult population. This gives a prevalence of APD treatment for the defined psychotic disorders in people also treated for epilepsy of 2.8%, and a prevalence of ASM treatment for epilepsy in people with psychosis of 3.1% (Table 2). There were 426 (48%) women and 465 (52%) men among the subjects with comorbid epilepsy and psychosis.

3.4. Directionality

The order of ASM and APD treatment in people with both epilepsy and psychosis is shown in Table 3. There were 558 subjects included in the analysis of directionality after the clean period 2004–2007. In 56% of the cases, the first APD was collected prior to the first ASM, whereas an ASM was collected first in 41%.

3.5. Antiseizure and antipsychotic drugs

Fig. 1A and B provides an overview of the distribution of ASMs and APDs collected twelve months prior to onset of comorbidity. Out of the 231 subjects collecting ASMs first, 41 (18%) had not...
collected an ASM during the last 12 months before starting an APD for psychosis (Fig. 1C). Ten patients in this group (24%) were ≤18 years of age when first collecting an APD, and 15 had been without ASM treatment for more than 5 years at the end of the study period, suggesting epilepsy in remission. Among the 190 subjects on epilepsy treatment at onset of psychosis, 72 (38%) used two or more APDs.

The average DDD/patient/day of ASMs for epilepsy was 1.0 in the epilepsy with psychosis group, compared to 1.1 in the group without comorbid psychosis (SD = 0.060 and 0.067 respectively), \( p = 0.021 \). For APDs the average DDD/patient/day was 0.99 (SD = 0.032) in the non-comorbid psychosis group, whereas topiramate, clonazepam, and valproic acid were used by more comorbid subjects without comorbid epilepsy group, whereas topiramate, clonazepam, and valproic acid were used by more comorbid subjects.

During the entire study period, carbamazepine and levetiracetam were both used by a larger proportion of subjects in the non-comorbid epilepsy group, whereas topiramate, clonazepam, and valproic acid were used by more comorbid subjects (Fig. 2A). For APDs levomepromazine, chlorprothixene, risperidone, and clozapine were used by more subjects with comorbid psychosis during this year (Fig. 2B). Among the 226 subjects treated for psychosis the final year before epilepsy onset, 36% had used two or more ASMs for epilepsy during the last year.

Olanzapine and quetiapine were the most frequent APDs used during the last twelve months before epilepsy onset. Eighty-four subjects (27%) had not collected an APD for psychosis during this year (Fig. 1C). Among the 226 subjects treated for psychosis the final year before epilepsy onset, 36% had used two or more APDs.

The average DDD/patient/day of ASMs for epilepsy was 1.0 in the epilepsy with psychosis group, compared to 1.1 in the group without comorbid psychosis (SD = 0.032 and 0.023 respectively), \( p < 0.001 \) (Table 4). For APDs the average DDD/patient/day was 1.0 (SD = 0.060) in the comorbidity group compared to 0.9 (SD = 0.067) in the non-comorbidity group, \( p = 0.021 \).

During the entire study period, carbamazepine and levetiracetam were both used by a larger proportion of subjects in the non-comorbid epilepsy group, whereas topiramate, clonazepam, and valproic acid were used by more comorbid subjects (Fig. 2A). For APDs levomepromazine, chlorprothixene, risperidone, and clozapine were used by more subjects with comorbid psychosis during this year (Fig. 2B).

### 4. Discussion

To our knowledge this is the first population-based study examining the directionality of ASM and APD treatment in subjects with comorbid epilepsy and psychosis. Based on first time prescriptions among comorbid subjects, the present study suggests that the proportion of people with established psychosis at epilepsy onset is higher than previously recognized [6]. More than half of the patients with comorbid epilepsy and psychosis were already treated with APDs when they started treatment for epilepsy (56%). The findings corroborate the assumption of shared neurobiological mechanisms for these two brain disorders, conceivably due to both structural and genetic traits [13–15]. However, individuals harboring this inherent predisposition may not develop either definite psychosis or manifest epileptic seizures without further exposure to provocative environmental and acquired factors [16]. These factors should receive ample attention in the comprehensive management of people with comorbid epilepsy and psychosis.

The bidirectionality of the two disorders forms two different clinical scenarios.

#### 4.1. Psychosis following epilepsy

In the current definition of epilepsy by the International League Against Epilepsy, the principal elements of the diagnosis were extended beyond recurrent seizures to also include “the neurobiological, cognitive, psychological, and social consequences of the condition” [17]. This definition highlights the perceived stigma and the restrictions associated with the disease and encompasses a vulnerability to develop psychiatric disorders in people with epilepsy. Apart from the psychosocial impact of the disorder, various disease consequences with potential to induce psychosis have been addressed in the literature.

Postictal and interictal psychosis usually follow long-standing severe and uncontrolled epilepsy [18–20]. Postictal psychosis is a temporary event developing within hours to days after a seizure or a cluster of seizures, particularly in temporal lobe epilepsy, often with conspicuous violent and religious elements [21–23]. The primary treatment is optimization of ASMs rather than long-term APDs [24–26]. Intercital psychosis is usually a chronic disorder resembling nuclear schizophrenia, but negative symptoms are less prominent and emotional responsiveness often preserved [16]. The sum of seizures over time appears to contribute to the vulnerability for this most common form of psychosis in epilepsy [19]. Intercital psychosis usually presents later in life compared to schizophrenia [27]. Consistent with this, in the present study the mean age at first collected APD for psychosis was 39 years in subjects with epilepsy first. It has been suggested that psychotic symptoms may be facilitated by harmful ictal effects on brain function by so-called “kindling” or by vascular factors [14,20,28], or even by subclinical activity in the limbic system undetectable by scalp EEG [29]. Alternative psychosis, or so-called “forced normalization” as reflected in the EEG, may be brought on by abrupt seizure control and could indicate a biological antagonism between psychosis and seizures [18,30]. Accordingly, by this mechanism any successful ASM or other intervention might have the potential to induce psychosis in vulnerable patients [31].

Moreover, several ASMs may cause psychiatric and behavioral pharmacodynamic adverse effects, affecting between 15–20% of...
adult patients, of which psychosis was specifically reported in 0.5% in one study [32]. Psychosis has been reported as an adverse effect from various ASMs. The ASMs most commonly involved include ethosuximide, levetiracetam, topiramate, zonisamide, and vigabatrin [31–34]. In the present study, levetiracetam, topiramate, or zonisamide were used by approximately 40% of the patients with epilepsy during the last year prior to APD onset. However, drug effects may be difficult to sort out in people predisposed to psychosis by other factors. Noteworthy, levetiracetam was less used during the entire study period among patients with psychosis compared to those without, probably reflecting avoidance of this drug in patients with psychiatric problems, whereas topiramate was more used. Kanemoto et al. found that 45 among 132 patients with epilepsy and interictal psychosis had added ASMs or increased the dose before psychosis onset, half of these were related to zonisamide [35]. It has been suggested that any ASM may contribute to the development of psychosis in predisposed individuals [36]; however, the daily dose of ASMs has not been significantly associated with psychosis [37]. We did not identify an increased load of ASMs as expressed by mean DDDS in the group of subjects with epilepsy and psychosis.

Interestingly, 18% of the subjects with epilepsy first had not collected any ASM during the last 12 months prior to the first APD for psychosis. A large portion of these subjects were of young age, some possibly with childhood epilepsy in remission. An association even between uncomplicated or self-limited epilepsies and psychiatric disorders has been suggested [2,38,39].

4.2. Epilepsy following psychosis

A range of seizure precipitating factors may occur in psychiatric disease, either by endogenous mechanisms in the form of severe emotional stress and lack of sleep, or by exogenous influences due to the exposure to compounds which may lower the seizure

---

**Fig. 2.** Medications used by subjects with or without comorbidity during the entire study period; (A) antiseizure medications, (B) antipsychotic drugs.
threshold. The pharmacological mechanisms comprise withdrawal effects from alcohol and benzodiazepines and direct neurotoxic effects from various drugs. A high load of APDs may induce seizures and increase the susceptibility to recurrent seizures in predisposed individuals [40]. Moreover, population-based data have shown that people with epilepsy are more often registered with substance use disorders than people without epilepsy, a comorbidity sometimes complicated by psychosis [41,42]. Abuse of various illicit drugs, such as cocaine and psychostimulants frequently precipitate seizures [43,44]. The association of substance use disorders and seizure disorders is a substantial clinical problem, as the borders between epilepsy and acute symptomatic seizures may be blurred [41]. Likewise, people with psychotic disorders may have an increased risk of developing focal epilepsy from various acquired causes, including head traumas associated with violent behavior and self-harm, as well as alcohol and drug intoxications [5,45].

Nearly all patients with long-lasting psychosis are treated with APDs. The impact of the seizure-inducing effects of these drugs in clinical practice has repeatedly been debated. Clozapine stands out as the drug with the most pronounced seizure-triggering effect. Clinical trial data in patients without epilepsy have also shown a higher risk of seizures for olanzapine and quetiapine than for ziprasidone, aripiprazole, and risperidone [26,46]. However, APD treatment, particularly clozapine, may also induce EEG slowing and epileptiform activity [47], leading to an unwarranted suspicion of epilepsy in some patients. Clozapine was used by nearly 15% of the subjects on APD treatment at onset of epilepsy. It had been used by a significantly larger proportion of subjects with epilepsy comorbidity during the entire study period. Clozapine should predominantly be prescribed when other APDs have failed, signifying difficult-to-treat psychosis [48]. Olanzapine and quetiapine were both used by almost 30%, whereas ziprasidone, risperidone, and aripiprazole were less used prior to epilepsy onset. Noteworthy, approximately one quarter of subjects with psychosis antedating epilepsy had not collected any APDs during the last year prior to onset of ASM treatment for epilepsy.

It has been emphasized that appropriate treatment of psychiatric disorders in people with epilepsy has been neglected due to an overestimated risk of seizures associated with APD treatment [1,26]. Some studies have even shown an improved seizure outcome in comorbid patients treated with careful APD regimens, possibly related to achieved control of psychiatric symptoms lessening seizure precipitants, including poor adherence to ASMs [5,40,49]. Nonetheless, data suggest that seizure induction is a dose-dependent class effect of APDs, which varies considerably among the numerous compounds [31,40,46]. A subset of people may be particularly vulnerable to this effect [40], and it is difficult to assess the real magnitude of this phenomenon in clinical practice. This study shows that the overall DDD burden of APDs for psychosis was significantly higher among subjects with epilepsy comorbidity compared to non-comorbid subjects. In some cases, an enzyme-inducing effect on APD serum concentrations from ASMs, such as carbamazepine, may underlie a need for higher doses [1]. The APD-treatment-response of people with epilepsy and psychosis compared to people with schizophrenia is still unknown [26], and psychosis in people with epilepsy might be more difficult to treat. The aim should be to treat people with epilepsy using the minimum effective doses of appropriate drugs [31], carefully considering seizure frequency as well as the total burden of adverse effects in subjects using various CNS-active drugs.

Any of the above discussed factors may worsen seizure control or even directly cause seizures and have to be considered in patients with comorbid seizures and psychiatric disease [28]. Such factors may frequently occur in concert and could conceivably have the potential to unveil a predisposition to developing epilepsy, sometimes with subthreshold effects adding to each other. These factors could explain why psychiatric disorders may lead to a worse response to the treatment of epilepsy [1,50].

4.3. Methodological issues

Antiseize and antipsychotic drugs are used for a wide range of symptoms. The manifestations of epilepsy and its related psychopathology can be atypical and diverse, and most prescriptions in our study were issued in primary care. We acknowledge that the diagnosis of epilepsy is sometimes demanding in people with psychosis due to occasional episodic nonspecific behaviors and intermittent extrapyramidal adverse reactions from APDs. Unfortunately, no information on the classification of epilepsy could be retrieved from the present dataset. Noteworthy, about one quarter of people with epilepsy also have intellectual disability [51]. In these patients, specific psychiatric diagnoses are difficult to identify. In a recent British study addressing polypharmacy in a selected cohort of people with intellectual disability and epilepsy, 27% used APDs, but only 7% had a comorbid diagnosis of psychosis. This suggests not only a higher prevalence of psychosis in people with intellectual disability and epilepsy, but also a higher proportion of APD treatment for non-psychotic conditions, such as unspecified challenging behaviors [52]. However, patients in the present population-based study were strictly selected by reimbursement codes for epilepsy and psychosis, aiming to minimize this potential confounder.

The main strength of this study is the inclusion of the entire adult Norwegian population over a 14-year period, using data from the NorPD, which is a validated source of pharmacoepidemiological studies [53,54]. To ensure long-term treatment, only subjects with ASMs or APDs collected at least four times for the respective diagnoses were included. To further enhance diagnostic validity, the ICD-10 coding system employed by the specialist healthcare services, had been used at least once. By this procedure, the prevalence of patients using ASMs for epilepsy and APDs for psychosis (0.8% for both groups) met fairly well with recent Norwegian population-based prevalence studies both for epilepsy (0.6%) [55], and for psychosis (0.6% for schizophrenia-spectrum disorders) [41]. Prescriptions for affective psychoses were not included. We acknowledge that collected treatment does not necessarily reflect used medication. Also, drugs administered in hospitals or institutions are not included in the NorPD.

An obvious limitation of the study is that we could hardly determine the true onset of treatment in all patients. Selecting a long clean period increases internal validity as pointed out by Roberts et al. [56], but we could not exclude intermittent treatments prior to this period. Nevertheless, this was considered less likely for ASMs than for APDs, as treatment for epilepsy is usually more stable and long-term than for psychosis. Hence, we consider that this possible bias might have influenced the results toward an even higher proportion of onset of treatment for psychosis first.

We also acknowledge that the clinical onset of epilepsy and psychosis may differ from both the time of diagnosis and treatment onset of these disorders. A single seizure may be left untreated until another occurs [57], and the onset of psychosis requiring treatment may obviously be difficult to define [58]. However, the general principles of early symptomatic treatment of psychotic symptoms also apply in epilepsy-related interictal psychoses [31].

5. Conclusion

The present study suggests that the proportion of patients with prior antipsychotic treatment at onset of epilepsy is higher than
previously acknowledged. This particular group of patients should receive more clinical and scientific attention. The bidirectional comorbidity of epilepsy and psychosis indicates a shared neurobiological susceptibility, but various environmental factors may also be at play, including the interaction of pharmacodynamic effects. AFDs may facilitate seizures, and ASMs may induce psychiatric symptoms. In patients with combined treatment, these potential drug effects should be carefully explored and monitored, along with the psychosocial and life-style consequences of the disorders. A comprehensive multi-professional approach is required. To broaden the understanding of the challenging association between psychosis and epilepsy, joint scientific and educational efforts between the fields of neurology and psychiatry should be reinforced.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Mula M, Kanner AM, Jetté N, Sander JW. Psychiatric comorbidities in people with epilepsy. Neuroul Clin Prac 2021;11(2):e112–20.
[2] Nakken EI, Crindle F, Vaaler A, Oranke OK, Brodtbok E, Steth SS. Epilepsy and other seizure disorders in acute psychiatric inpatients. BMC Psychiatry 2021;21:626.
[3] Clancy MJ, Clark MC, Connor DJ, Cannon M, Cotter DR. The prevalence of psychosis in epilepsy: a systematic review and meta-analysis. BMC Psychiatry 2014;14:75.
[4] Slater E, Board AW. The Schizophrenia-like psychoses of epilepsy: I. Psychiatric Aspects. Br J Psychiatry 1963;109:95–112.
[5] Adachi N, Ito M. Epilepsy in patients with schizophrenia: Pathophysiology and basic treatments. Epilepsy Behav 2022;127:108520.
[6] Adachi N, Onuma T, Kato M, Ito M, Akanuma N, Hara T, et al. Analogy between psychosis antedating epilepsy and epilepsy antedating psychosis. Epilepsia 2011;52:1239–44.
[7] Adelow C, Andersson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders in older adults: data from U.S. Medicare beneficiaries. Epilepsia 2014;55(2):208–13.
[8] Wotton CJ, Goldacre MJ. Coexistence of schizophrenia and epilepsy: Record linkage studies. Epilepsia 2012;53:e71–4.
[9] Hesdorfer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 2012;72(2):184–91.
[10] Erttinger AB, Copeland LA, Zeber JE, Cott AC, Pugh MJV. Are psychiatric disorders independent risk factors for incident cases of new-onset epilepsy in older individuals? Epilepsy Behav 2010;17(1):70–4.
[11] Martin RC, Faught E, Richman J, Funkhouser E, Kim Y, Clements K, et al. Psychiatric and neurologic risk factors for incident cases of new-onset epilepsy in older adults: data from U.S. Medicare beneficiaries. Epilepsia 2014;55(7):1120–7.
[12] SBS. Statistics Norway Population count. In: https://www.ssb.no/en/statbank accessed 23/05/2022; 2022.
[13] Clarke MC, Tanskanen A, Huttunen MO, Clancy M, Cotter DR, Cannon M. Evidence for shared susceptibility to epilepsy and psychosis: A population-based family study. Biol Psychiatry 2012;71(9):836–9.
[14] Maguire J. Mechanisms of psychiatric comorbidities in epilepsy. In: Jones NC, Kanner AM, editors. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2017:76:24–31.
[15] Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2017:76:24–31.
[16] Kanner AM. Do psychiatric comorbidities have a negative impact on the outcome of epilepsy treatment? Adv Neurol Disord 2012;56:231–34.
[17] Kanemoto K, Tadokoro Y, Oshima T. Violence and postictal psychosis: a comparison of postictal psychosis, interictal psychosis, and postictal confusion. Epilepsia 2008;49(12):162–6.
[18] Oshima T, Tadokoro Y, Kanemoto K. A prospective study of postictal psychoses with emphasis on the perictal type. Epilepsia 2006;47:2131–4.
[19] Devinsky O. Postictal psychosis: common, dangerous, and treatable. Epilepsy Curr 2008;8(2):3–7.
[20] Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry 1998;155(3):325–36.
[21] Kanemoto K, Tadokoro Y, Oshima T. Psychotic illness in patients with epilepsy. Ther Adv Neurol Disord 2010;19(2):162–6.
[22] Oshima T, Tadokoro Y, Kanemoto K, et al. Difference in age of onset of psychosis between epilepsy and schizophrenia. Epilepsia 2008;78(2–3):201–6.
[23] Smith PF, Darlington CL. The development of psychosis in epilepsy: a re-examination of the kindling hypothesis. Behav Brain Res 1996;75(1-2):59–66.
[24] Boutros NN, Bowyer S, Wang J, Ufry MZ, Loeb JA. Epilepsy spectrum disorders: A concept in need of validation or refutation. Med Hypotheses 2015;85(5):656–63.
[25] Calle-López Y, Ladino LD, Benjumea-Cuarte V, Castrillón-Velilla DM, Teléz-Zenteno JF, Wolf P. Forced normalization: A systematic review. Epilepsia 2019;60(8):1610–8.
[26] de Toffol T, Trumble M, Hesdorffer DC, Taylor L, Sachdev P, Clancy M, et al. Pharmacotherapy in patients with epilepsy and psychosis. Epilepsy Behav 2018;88:54–60.
[27] Chen Z, Lusiniec A, O'Brien TJ, Velakoulis D, Adams SJ, Kwan P. Psychotic disorders induced by antiepileptic drugs in people with epilepsy. Brain 2016;139(10):2068–78.
[28] Mula M, Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epilepsie Disord 2009;11:1–9.
[29] Kanemoto K, Tsuchi T, Kawasaki J. Reexamination of interictal psychoses based on DSM IV psychosis classification and international epilepsy classification. Epilepsia 2001;42:98–103.
[30] Akanuma N, Adachi N, Fenwick P, Ito M, Okazaki M, Hara K, et al. Individual vulnerabilities to psychosis after antiepileptic drug administration. BMJ Neurol Open 2020;2(2):e000036.
[31] Adachi N, Fenwick P, Akanuma N, Hara K, Ishii R, Okazaki M, et al. Increased frequency of psychosis after second-generation antiepileptic drug administration in adults with focal epilepsy. Epilepsy Behav 2019;57:138–43.
[32] Asberg KM, Bakken IJ, Lossius MJ, Lund Saraas C, Hiaberg SE, Stoltenberg C, et al. Comorbidity and childhood epilepsy: A population registry study. Pediatrics 2016;138:e20160021.
[33] Jällie M, Sillanpaa M. Concurrent illnesses in adults with childhood-onset epilepsy: A population-based 35-year follow-up study. Epilepsia 1996;37(12):1155–63.
[34] Pisani F, Oteri G, Costa D, di Raimondo G, di Perri R. Effects of psychotropic Neuroleptics on drug serum levels in epileptic patients. Drug Res 2002(25)(2):91–100.
[35] Bakken IJ, Revdal E, Næsvag R, Brenner E, Knudsen GP, Suren P, et al. Substance use disorders and psychotic disorders in epilepsy: a population-based registry study. Epilepsy Res 2014;108:433–45.
[36] Selassie AW, Wilson DA, Marrt GJ, Smith GG, Wagner JT, Wannamaker BB. Epilepsy beyond seizure: A population-based study of comorbidities. Epilepsy Res 2014;108(2):305–15.
[37] Leach JP, Moharram R, Borland W. Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention. Epilepsia 2012;53(Suppl 4):48–57.
[38] Lappin JM, Sara GE. Psychostimulant use and the brain. Addiction 2010;114(11):2065–77.
[39] Makrygiou T, Karvonen JT, Hakko H, Nieminen P, Joukamaa M, Isohanni M, et al. Comorbidity of hospital-treated psychiatric and physical disorders with special reference to schizophrenia: a 28 year follow-up of the 1966 Northern Finland general population birth cohort. Public Health 1998;112(4):221–8.
[40] Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62(8):345–54.
[41] Jackson A, Seneviratne UE. EEG changes in patients on antipsychotic therapy: A systematic review. Epilepsia Behav 2019;95:1–9.
[42] Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehen M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry 2017;62(9):604–16.
[43] Okazaki M, Adachi N, Akanuma N, Hara K, To M, Kato M, et al. Do antipsychotic drugs increase seizure frequency in epilepsy patients? Eur Neuropsychopharmacol 2014;24(17):1738–44.
[44] Kanner AM. Do psychiatric comorbidities have a negative impact on the course and treatment of seizure disorders? Curr Opin Neurol 2013;26(2):208–13.
[51] McGrother CW, Bhaumik S, Thorp CF, Hauck A, Branford D, Watson JM. Epilepsy in adults with intellectual disabilities: prevalence, associations and service implications. Seizure 2006;15(6):376–86.

[52] Sun JJ, Perera B, Henley W, Angus-Leppan H, Sawhney I, Watkins I, et al. Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study. J Neurol 2022;269(5):2750–60.

[53] Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD)-new opportunities for research in pharmacoepidemiology in Norway. Norwegian J Epidemiol 2008;18:129–36.

[54] Wettermark B, Zoëga H, Furu K, Korhonen M, Hållas J, Nørgaard M, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research—a literature review. Pharmacoepidemiol Drug Saf 2013;22(7):691–9.

[55] Syvertsen M, Nakken KO, Edland A, Hansen G, Hellum MK, Koht J. Prevalence and etiology of epilepsy in a Norwegian county-A population based study. Epilepsia 2015;56(5):699–706.

[56] Roberts AW, Dusetzina SB, Farley JF. Revisiting the washout period in the incident user study design: why 6–12 months may not be sufficient. J Comp Eff Res 2015;4(1):27–35.

[57] Sharma S, Kwan P. The safety of treating newly diagnosed epilepsy. Expert Opin Drug Saf 2019;18(4):273–83.

[58] Chan V. Schizophrenia and psychosis: diagnosis, current research trends, and model treatment approaches with implications for transitional age youth. Child Adolesc Psychiatr Clin N Am 2017;26(2):341–66.